Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Products under Development by Stage of Development | 8 | 1 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Products under Development by Therapy Area | 9 | 1 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Products under Development by Indication | 10 | 1 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Products under Development by Companies | 13 | 2 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Products under Development by Universities/Institutes | 15 | 2 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 1 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Companies Involved in Therapeutics Development | 22 | 2 |
| Ensemble Therapeutics Corporation | 22 | 1 |
| NeuroVive Pharmaceutical AB | 23 | 1 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Drug Profiles | 24 | 13 |
| cyclosporine Drug Profile | 24 | 5 |
| cyclosporine Drug Profile | 29 | 1 |
| NVP-014 Drug Profile | 30 | 1 |
| NVP-015 Drug Profile | 31 | 1 |
| NVP-018 Drug Profile | 32 | 2 |
| NVP-019 Drug Profile | 34 | 1 |
| Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis Drug Profile | 35 | 1 |
| Small Molecules to Inhibit Cyclophilin D for Cardiovascular and Central Nervous System Drug Profile | 36 | 1 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Dormant Projects | 37 | 2 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Discontinued Products | 39 | 1 |
| Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Featured News &Press Releases | 40 | 12 |
| Jun 07, 2016: NeuroVive announces CiPRICS study completes enrolment | 40 | 1 |
| Apr 28, 2016: NeuroVive s R&D Team to Present Research Progress at Mitochondrial Medicine Conference | 41 | 1 |
| Mar 14, 2016: NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation | 41 | 1 |
| Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study | 42 | 1 |
| Nov 02, 2015: NeuroVive Pharmaceutical: NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress | 43 | 1 |
| Oct 28, 2015: NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus | 43 | 1 |
| Aug 30, 2015: Cyclosporine Does Not Improve Outcomes After PCI | 44 | 1 |
| Jun 01, 2015: Neurovive Reports Topline Results of Phase III CIRCUS Study in Acute Myocardial Infarction | 44 | 2 |
| May 25, 2015: Neurovive Pharmaceutical: Topline Result of Phase III Study of Ciclomulsion in Acute Myocardial Infarction Expected This Quarter | 46 | 1 |
| May 07, 2015: Neurovive Pharmaceutical: Published Data Indicates Protective Effect of Cyclosporine in Patients with Stroke | 46 | 1 |
| Apr 27, 2015: FIrst Patient Enrolled in Clinical Phase II Study for Kidney Protection During Heart Surgery | 47 | 1 |
| Apr 21, 2015: Clinical Phase II Study with NeuroSTAT for Traumatic Brain Injury Passes Safety Evaluation | 48 | 1 |
| Apr 17, 2015: Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics | 49 | 1 |
| Dec 02, 2014: NeuroVive and Skane University Hospital initiate collaboration on clinical phase II study on kidney protection during heart surgery | 50 | 1 |
| Aug 14, 2014: Neurovive Pharmaceutical Announces Enrollment To Phase II Study On NeuroSTAT Continues | 51 | 1 |
| Appendix | 52 | 2 |
| Methodology | 52 | 1 |
| Coverage | 52 | 1 |
| Secondary Research | 52 | 1 |
| Primary Research | 52 | 1 |
| Expert Panel Validation | 52 | 1 |
| Contact Us | 52 | 1 |
| Disclaimer | 53 | 1 |
